当前位置: X-MOL 学术Cancer Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CD146 is a potential immunotarget for neuroblastoma
Cancer Science ( IF 4.5 ) Pub Date : 2021-08-31 , DOI: 10.1111/cas.15124
Satoshi Obu 1 , Katsutsugu Umeda 1 , Hiroo Ueno 1 , Mari Sonoda 2 , Keiji Tasaka 1 , Hideto Ogata 1 , Kagehiro Kouzuki 1 , Seishiro Nodomi 1 , Satoshi Saida 1 , Itaru Kato 1 , Hidefumi Hiramatsu 1 , Tatsuya Okamoto 2 , Eri Ogawa 2 , Hideaki Okajima 2, 3 , Ken Morita 4 , Yasuhiko Kamikubo 4 , Koji Kawaguchi 5 , Kenichiro Watanabe 5 , Hideto Iwafuchi 6 , Shigeki Yagyu 7 , Tomoko Iehara 7 , Hajime Hosoi 7 , Tatsutoshi Nakahata 8 , Souichi Adachi 4 , Shinji Uemoto 2 , Toshio Heike 1 , Junko Takita 1
Affiliation  

Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to arise from neural crest-derived immature cells. The prognosis of patients with high-risk or recurrent/refractory neuroblastoma remains quite poor despite intensive multimodality therapy; therefore, novel therapeutic interventions are required. We examined the expression of a cell adhesion molecule CD146 (melanoma cell adhesion molecule [MCAM]) by neuroblastoma cell lines and in clinical samples and investigated the anti-tumor effects of CD146-targeting treatment for neuroblastoma cells both in vitro and in vivo. CD146 is expressed by 4 cell lines and by most of primary tumors at any stage. Short hairpin RNA-mediated knockdown of CD146, or treatment with an anti-CD146 polyclonal antibody, effectively inhibited growth of neuroblastoma cells both in vitro and in vivo, principally due to increased apoptosis via the focal adhesion kinase and/or nuclear factor-kappa B signaling pathway. Furthermore, the anti-CD146 polyclonal antibody markedly inhibited tumor growth in immunodeficient mice inoculated with primary neuroblastoma cells. In conclusion, CD146 represents a promising therapeutic target for neuroblastoma.

中文翻译:

CD146 是神经母细胞瘤的潜在免疫靶点

神经母细胞瘤是儿童时期最常见的颅外实体瘤,被认为起源于神经嵴衍生的未成熟细胞。尽管进行了强化的多模式治疗,但高危或复发/难治性神经母细胞瘤患者的预后仍然很差;因此,需要新的治疗干预措施。我们检查了神经母细胞瘤细胞系和临床样本中细胞粘附分子 CD146(黑色素瘤细胞粘附分子 [MCAM])的表达,并在体外和体内研究了 CD146 靶向治疗对神经母细胞瘤细胞的抗肿瘤作用。CD146 由 4 种细胞系和任何阶段的大多数原发性肿瘤表达。短发夹 RNA 介导的 CD146 敲低,或用抗 CD146 多克隆抗体处理,在体外和体内均有效抑制神经母细胞瘤细胞的生长,主要是由于通过粘着斑激酶和/或核因子-κB 信号通路增加细胞凋亡。此外,抗 CD146 多克隆抗体显着抑制了接种原代神经母细胞瘤细胞的免疫缺陷小鼠的肿瘤生长。总之,CD146 代表了神经母细胞瘤的一个有希望的治疗靶点。
更新日期:2021-08-31
down
wechat
bug